{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:37:11Z","timestamp":1783413431627,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11606-022-07778-w","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T17:03:25Z","timestamp":1663693405000},"page":"865-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014\u20132020"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-9925","authenticated-orcid":false,"given":"Marguerite E.","family":"Beiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah C.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giavanna A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija O.","family":"Muse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanna K.","family":"Shores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis P.","family":"Baggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"7778_CR1","doi-asserted-by":"publisher","unstructured":"Noska AJ, Belperio PS, Loomis TP, O'Toole TP, Backus LI. Engagement in the hepatitis C care cascade among homeless veterans, 2015. Public Health Rep. 2017;132(2):136-139. https:\/\/doi.org\/10.1177\/0033354916689610.","DOI":"10.1177\/0033354916689610"},{"key":"7778_CR2","doi-asserted-by":"crossref","unstructured":"Gelberg L, Robertson MJ, Arangua L, et al. Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep. 2012;127(4):407-21.","DOI":"10.1177\/003335491212700409"},{"key":"7778_CR3","doi-asserted-by":"publisher","unstructured":"Strehlow AJ, Robertson MJ, Zerger S, et al. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved. 2012;23(2):811-33. https:\/\/doi.org\/10.1353\/hpu.2012.0047.","DOI":"10.1353\/hpu.2012.0047"},{"key":"7778_CR4","doi-asserted-by":"publisher","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020-1031. https:\/\/doi.org\/10.1002\/hep.30297.","DOI":"10.1002\/hep.30297"},{"key":"7778_CR5","unstructured":"World Health Organization. Global hepatitis report 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/255016."},{"key":"7778_CR6","unstructured":"World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. https:\/\/www.who.int\/publications\/i\/item\/9789241550345; July 2018."},{"key":"7778_CR7","doi-asserted-by":"publisher","unstructured":"Feld JJ, Ward JW. Key Elements on the pathway to HCV elimination: lessons learned from the AASLD HCV Special Interest Group 2020. Hepatol Commun. 2021;5(6):911-922. https:\/\/doi.org\/10.1002\/hep4.1731.","DOI":"10.1002\/hep4.1731"},{"key":"7778_CR8","doi-asserted-by":"publisher","unstructured":"Hashim A, Macken L, Jones A, McGeer M, Aithal G, Verma S. Community-based assessment and treatment of hepatitis C virus-related liver disease, injecting drug and alcohol use amongst people who are homeless: a systematic review and meta-analysis. Int J Drug Policy. 2021;96:103342. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103342.","DOI":"10.1016\/j.drugpo.2021.103342"},{"key":"7778_CR9","doi-asserted-by":"publisher","unstructured":"Corcorran MA, Tsui JI, Scott JD, Dombrowski JC, Glick SN. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington. Drug Alcohol Depend. 2021;220:108525. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108525.","DOI":"10.1016\/j.drugalcdep.2021.108525"},{"key":"7778_CR10","doi-asserted-by":"publisher","unstructured":"Falade-Nwulia O, Sacamano P, McCormick SD, et al. Individual and network factors associated with HCV treatment uptake among people who inject drugs. Int J Drug Policy. 2020;78:102714. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102714.","DOI":"10.1016\/j.drugpo.2020.102714"},{"key":"7778_CR11","doi-asserted-by":"publisher","unstructured":"Valerio H, Alavi M, Silk D, et al. Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa571.","DOI":"10.1093\/cid\/ciaa571"},{"key":"7778_CR12","doi-asserted-by":"publisher","unstructured":"Ziff J, Vu T, Dvir D, et al. Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City. Harm Reduct J. 2021;18(1):38. https:\/\/doi.org\/10.1186\/s12954-021-00486-4.","DOI":"10.1186\/s12954-021-00486-4"},{"key":"7778_CR13","doi-asserted-by":"publisher","unstructured":"Hodges J, Reyes J, Campbell J, Klein W, Wurcel A. Successful implementation of a shared medical appointment model for hepatitis C treatment at a community health center. J Community Health. 2018. https:\/\/doi.org\/10.1007\/s10900-018-0568-z.","DOI":"10.1007\/s10900-018-0568-z"},{"key":"7778_CR14","doi-asserted-by":"publisher","unstructured":"Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy. 2019;72:129-137. https:\/\/doi.org\/10.1016\/j.drugpo.2019.03.017.","DOI":"10.1016\/j.drugpo.2019.03.017"},{"key":"7778_CR15","doi-asserted-by":"publisher","unstructured":"Read P, Gilliver R, Kearley J, et al. Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection. J Viral Hepat. 2019;26(11):1301-1310. https:\/\/doi.org\/10.1111\/jvh.13175.","DOI":"10.1111\/jvh.13175"},{"key":"7778_CR16","doi-asserted-by":"crossref","unstructured":"Harney BL, Whitton B, Lim C, et al. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int J Drug Policy. 2019.","DOI":"10.1016\/j.drugpo.2019.02.012"},{"key":"7778_CR17","unstructured":"AASLD-IDSA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org."},{"key":"7778_CR18","doi-asserted-by":"publisher","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6. https:\/\/doi.org\/10.1002\/hep.21669.","DOI":"10.1002\/hep.21669"},{"key":"7778_CR19","doi-asserted-by":"publisher","unstructured":"Darvishian M, Wong S, Binka M, et al. Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat. 2019. https:\/\/doi.org\/10.1111\/jvh.13228.","DOI":"10.1111\/jvh.13228"},{"key":"7778_CR20","doi-asserted-by":"publisher","unstructured":"Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754-767. https:\/\/doi.org\/10.1016\/S2468-1253(18)30304-2.","DOI":"10.1016\/S2468-1253(18)30304-2"},{"key":"7778_CR21","doi-asserted-by":"crossref","unstructured":"Litwin AH, Lum PJ, Taylor LE, et al. A multisite randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: the HERO Study - Hepatitis C Real Options 2020.","DOI":"10.1016\/j.cct.2019.105859"},{"key":"7778_CR22","doi-asserted-by":"publisher","unstructured":"Morris MD, Mirzazadeh A, Evans JL, et al. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated. Drug Alcohol Depend. 2019;198:133-135. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.008.","DOI":"10.1016\/j.drugalcdep.2019.02.008"},{"key":"7778_CR23","doi-asserted-by":"publisher","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u2018Hep C\u2019s like the common cold\u2019: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246-254. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.013.","DOI":"10.1016\/j.drugalcdep.2018.06.013"},{"key":"7778_CR24","doi-asserted-by":"publisher","unstructured":"Burgess SV, Hussaini T, Yoshida EM. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: a concise review. Ann Hepatol. 2016;15(2):154-9. https:\/\/doi.org\/10.5604\/16652681.1193693.","DOI":"10.5604\/16652681.1193693"},{"key":"7778_CR25","doi-asserted-by":"publisher","unstructured":"Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41-5. https:\/\/doi.org\/10.1002\/hep.27366.","DOI":"10.1002\/hep.27366"},{"key":"7778_CR26","unstructured":"Sulkowski M, Feld J, Reau N, et al. Concordance between SVR4, SVR12, and SVR24 in HCV-infected. Patients who received fixed-dose combination sofosbuvir\/velpatasvir in phase 3 clinical trials. Poster presented at: International Liver Congress; June 23-26, 2021 2021; virtual. Accessed 6\/29\/22."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-022-07778-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:08:49Z","timestamp":1695168529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-022-07778-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["7778"],"URL":"https:\/\/doi.org\/10.1007\/s11606-022-07778-w","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}